Grisaru-Granovsky Sorina, Salah Zaidoun, Maoz Myriam, Pruss Diana, Beller Uziel, Bar-Shavit Rachel
Department of Oncology, Hadassah-Hebrew University Hospital, Jerusalem, Israel.
Int J Cancer. 2005 Jan 20;113(3):372-8. doi: 10.1002/ijc.20607.
Protease activated receptors (PAR) form a family of G-protein coupled receptors (GPCR) encoding their own ligands and uniquely activated via proteolytic cleavage. Although proteases in general have been implicated in the remodeling of the extracellular tumor microenvironment, the role of cell surface receptors activated by proteolysis is now emerging. In our present study we investigated the expression pattern of protease activated receptor 1 hPar1 in ovarian carcinoma tissue samples. Abundant hPar1 mRNA and protein were detected in "low malignant potential" and in invasive carcinomas, regardless of the histological subtype. In contrast, no hPar1 expression was detected on the cell surface of normal ovarian epithelium. The differential expression pattern of hPar1 was shown by in situ hybridization, immunohistochemistry and semi-quantitative RT-PCR analyses. In early stages of ovarian carcinoma (Ia), the contra lateral normal ovary showed strong PAR1 expression as opposed to the lack of expression in the ovarian epithelium obtained from normal individuals. In parallel, we analyzed the expression pattern of alphavbeta5 integrin and of activated focal adhesion kinase (FAK), a major focal contact protein, in these tissues. Although abundant expression of alphavbeta5 integrin was observed in all tissues specimens examined, regardless of either normal or malignant, the level of activated FAK was differentially expressed. Phosphorylated FAK was seen in invasive ovarian carcinoma, but not in the normal ovarian epithelium. The abundant hPar1 levels in pathological malignant ovarian carcinoma is likely to transmit signals leading to the phosphorylation of FAK and thereby alterations in the integrin functional state. Altogether our data suggest that hPar1 and FAK cooperate to promote ovarian cancer malignancy.
蛋白酶激活受体(PAR)构成了一类G蛋白偶联受体(GPCR)家族,它们编码自身的配体,并通过蛋白水解切割而独特地被激活。虽然一般来说蛋白酶与细胞外肿瘤微环境的重塑有关,但现在由蛋白水解激活的细胞表面受体的作用正在显现。在我们目前的研究中,我们调查了蛋白酶激活受体1(hPar1)在卵巢癌组织样本中的表达模式。在“低恶性潜能”肿瘤和浸润性癌中均中均检测到丰富的hPar1 mRNA和蛋白,无论组织学亚型如何。相比之下,在正常卵巢上皮细胞表面未检测到hPar1表达。通过原位杂交、免疫组织化学和半定量RT-PCR分析显示了hPar1的差异表达模式。在卵巢癌早期(Ia期),对侧正常卵巢显示出强烈的PAR1表达,而正常个体的卵巢上皮中则缺乏表达。同时,我们分析了这些组织中αvβ5整合素和活化的粘着斑激酶(FAK,一种主要的粘着斑蛋白)的表达模式。尽管在所有检查的组织标本中均观察到αvβ5整合素的丰富表达,无论正常还是恶性,但活化的FAK水平存在差异表达。磷酸化的FAK见于浸润性卵巢癌,而不见于正常卵巢上皮。病理性恶性卵巢癌中丰富的hPar1水平可能传递信号导致FAK磷酸化,从而改变整合素的功能状态。总之,我们的数据表明hPar1和FAK协同促进卵巢癌的恶性进展。